Amy Dickey, MD
Pulmonary Disease · Seattle, WANPI 1295034429
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,559 of the $71,093 with a category attached, or 64.1%. 5 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 52.4% of the total. Reporting peaked in 2024 at $29,511 and has fallen 63.3% since, to $10,839 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $1269.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$37K
- Recordati_rare_diseases_inc.$32K
- Tanabe Pharma America, Inc.$2K
- EUSA Pharma (US) LLC$157
- Mitsubishi Tanabe Pharma Development America, Inc.$115
Across 68 payments — averaging $3433.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$233K
What the payments were for
- Consulting fees$45,55964%
- Speaking & faculty fees$4,5526%
- Travel & lodging$20,14428%
- Food & beverage$8381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 38 | $37,280 |
| Recordati_rare_diseases_inc. | 14 | $31,816 |
| Tanabe Pharma America, Inc. | 1 | $1,725 |
| EUSA Pharma (US) LLC | 2 | $157 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANHEMATIN$31,644
- GIVLAARI$18,048
- GIVLARRI$6,967
How this compares
$71,093 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Seattle
- Jed GordenSeattle$236K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Jeffrey CarySeattle$106K
- Lawrence HoSeattle$70K
- Christopher GossSeattle$44K
- Reena MehraSeattle$36K
- Rebecca SellSeattle$30K
- Peter LearySeattle$27K
- Mark WurfelSeattle$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.